about
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveEffect of pitavastatin on vascular reactivity in hypercholesterolemic rabbitsKey questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin.JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin.Adverse drug reaction: rosuvastatin as a cause for ischaemic colitis in a 64-year-old woman.A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat heartsStatin intake is associated with MMP-1 level in gingival crevicular fluid of patients with periodontitis.Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects.Emerging options in the treatment of dyslipidemias: a bright future?Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms.The effect of statins on the organs: similar or contradictory?Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?Erythromelalgia accompanying rosuvastatin-associated myopathy.Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells.Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.Efficacy and safety of rosuvastatin in late-onset hypogonadism patients with dyslipidaemia.Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.Statins and mortality: the untold story.Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy
P2860
Q24594814-C16AA3F3-97CF-447C-97B9-B274BC5AA7B3Q34020643-4BA10095-35DD-422B-9109-4677925F5036Q34390605-52035A8B-8782-4313-BC3A-C688BF190366Q35172886-1DCC1CB1-D803-4382-8D9D-1238D35BB15CQ36127865-0317E672-2C0B-4EE2-8F35-6D7EE51130FEQ36251259-6E667256-B7D4-4175-98E2-BE598777EB53Q36577081-5F6B2194-06DD-40AB-9D31-652E415DCB79Q36984463-E673C63B-C840-4A29-A94F-F81CA201740FQ37242876-71FA5089-A4A9-4983-B4DF-8BE0A473A06DQ37842462-40535EEB-22C4-43BD-8C53-17D17D0F437CQ38208727-7D17CCAB-C280-4B0E-97DE-8BA8D183CB04Q38434603-FA608B51-F1BC-4E24-917C-7118FA300225Q39052351-395F36CB-08C8-4BBF-9BBE-9752383E0268Q39455897-47A43F83-F5F2-4078-BB0F-F90655F2F8CDQ39515241-86194E82-EE21-4702-BF7A-DF2B3CA3CCBFQ42727132-8BF40F98-754F-4879-81A3-2D9EB3CF48FCQ43127805-82B7D1EA-D092-4479-973A-D1B260F771E8Q43282310-42B5AA06-F0B1-42FE-9F5B-886A1E5FCA4AQ45860083-5E5FCCFA-496A-41F0-8D74-16395ED0DEEEQ45990981-2E0B5584-7976-48AD-885A-B23B899459F4Q53645752-FDE22DBE-42CD-4B25-9801-E301B68373A9Q58294593-EF093D39-739B-470B-B75A-8116D12CCBB3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An overview of the extra-lipid effects of rosuvastatin.
@en
An overview of the extra-lipid effects of rosuvastatin.
@nl
type
label
An overview of the extra-lipid effects of rosuvastatin.
@en
An overview of the extra-lipid effects of rosuvastatin.
@nl
prefLabel
An overview of the extra-lipid effects of rosuvastatin.
@en
An overview of the extra-lipid effects of rosuvastatin.
@nl
P2860
P356
P1476
An overview of the extra-lipid effects of rosuvastatin
@en
P2093
Haralampos J Milionis
P2860
P304
P356
10.1177/1074248408318628
P577
2008-05-06T00:00:00Z